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Abstract
Sickness behavior is a cluster of symptoms that occur as a response to an infection and alterations in the
inflammatory response. Under normal circumstances, sickness behavior is fully reversible once the pathogen
has been cleared. Aging and chronic illness such as heart failure are associated with enhanced inflammatory
activity that lasts for a long duration and no longer represents an adaptive response. The aim of this study was
to explore whether inflammation mediates the relationship between impaired cardiac function and a symptom
cluster including anhedonia, fatigue, and sleepiness, which might represent sickness behavior in community-
dwelling elders. Structural equation modeling (SEM) showed that the factor impaired cardiac function (i.e.,
N-terminal fragment of pro-brain natriuretic peptide, left ventricular ejection fraction, and the heart failure
medications angiotensin converting enzyme inhibitor, angiotensin receptor blockade, β-blocker, and
diuretics) was associated with both inflammation (i.e., C-reactive protein; β = .26) and the symptom cluster
(β = .31). Inflammation had a significant direct, but smaller, association with the symptom cluster (β = .21).
By this pathway, inflammation also mediated an indirect association between impaired cardiac function and
the symptom cluster (β = .05). Including creatinine, blood glucose, ischemic heart disease, previous and
current tumor, respiratory disease, age, and body mass index in the SEM model did not change these
associations. Our results imply that some aspects of the symptom panorama in elderly individuals with
impaired cardiac function or heart failure could represent sickness behavior.
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Abstract  
Sickness behavior is a cluster of symptoms such as anhedonia, fatigue and sleepiness that 
occurs as a response to an infection and alterations in the inflammatory response. Under 
normal circumstances sickness behavior is fully reversible once the pathogen has been 
cleared. Aging and chronic illness such as heart failure are associated with enhanced 
inflammatory activity that lasts for a long duration and no longer represents an adaptive 
response. The aim of this study was to describe sickness behavior in community dwelling 
elders and to test the hypothesis that inflammation mediates the relationship between impaired 
cardiac function and sickness behavior. Structural equation modelling (SEM) showed that the 
factor impaired cardiac function (i.e. NT-proBNP, left ventricular ejection fraction (LVEF) 
and the heart failure medications angiotensin converting enzyme inhibitor, angiotensin 
receptor blockade, beta-blocker and diuretics) was associated with both inflammation (i.e. C-
reactive protein [CRP]) (β=.26) and sickness behavior (β=.31). Inflammation had a significant 
direct, but smaller, association with sickness behavior (β=.21). By this pathway inflammation 
also mediated an indirect association between impaired cardiac function and sickness 
behavior (β=.05). Including creatinine, blood glucose and ischemic heart disease, previous 
and current tumor, respiratory disease, age, and body mass index in the SEM model did not 
change these associations. In community dwelling elders, impaired cardiac function and 
inflammation were associated with a symptom cluster consisting of anhedonia, fatigue and 
sleepiness. Our results imply that some aspects of the symptom panorama in elderly with 
impaired cardiac function or heart failure could represent sickness behaviour.  
Keywords: Heart failure, elderly, inflammation, sickness behavior 
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Background 
Sickness behavior is a cluster of symptoms that occurs as a response to infection and 
alterations in the inflammatory response. Characteristics of sickness behaviors such as loss of 
energy or fatigue, somnolence, loss of interest in usual activities (anhedonia), poor appetite, 
weight changes and malaise serve as an adaptive response to conserve energy and resources in 
order to promote the resistance to pathogens and recovery from infection (Dantzer, 2006; 
Kelley, et al., 2003; Myers, 2008). Sickness behavior is, under normal circumstances, fully 
reversible once the pathogen has been cleared (Dantzer, O'Connor, Freund, Johnson, & 
Kelley, 2008).  
Aging is associated with enhanced production of pro-inflammatory cytokines and can be said 
to be typified as a low grade inflammatory state (Hunt, Walsh, Voegeli, & Roberts, 2010a, 
2010b). Studies have shown that aspects of sickness behavior such as depressive symptoms 
(Stordal, Mykletun, & Dahl, 2003) and sleep disturbances (Newman, Enright, Manolio, 
Haponik, & Wahl, 1997) are common among the elderly. These disturbances are also 
associated with increased cytokine concentrations (Penninx, et al., 2003; von Kanel, et al., 
2006) and thus, aging itself may contribute to sickness behavior. Another condition associated 
with aging and inflammation is impairment of cardiac function and heart failure (Anker & 
von Haehling, 2004; Pasic, Levy, & Sullivan, 2003; Shih, Lee, Lee, & Boyle, 2011).  
Impairment of cardiac function in heart failure can be defined as a reduced left 
ventricular ejection fraction (LVEF) below 50%. The measurement of LVEF is 
preferably performed with echocardiography and based on the end diastolic volume 
minus the end systolic volume divided by the end diastolic volume. Another commonly 
used measure of heart failure is N-terminal fragment of pro-brain natriuretic peptide 
(NT-proBNP) (McMurray, et al., 2012). This peptide provides information about 
myocardial wall-tension and is sensitive to subtle alterations in left ventricular filling 
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pressures (Alehagen, Lindstedt, Eriksson, & Dahlstrom, 2003). Treatment of heart 
failure and/or impaired cardiac function with angiotensin converting enzyme inhibitors 
(ACE-I), angiotensin receptor blockade (ARB), beta-blockers, and diuretics has proved 
to reduce symptoms such as oedema, and improve cardiac function (McMurray, et al., 
2012). In heart failure, inflammation may be due to myocardial tissue injury and 
impairment of cardiac function with hemodynamic overload and/or under-perfusion of 
systemic tissues (Pasic, et al., 2003) as well as gut wall oedema (Sandek, et al., 2010). 
Impaired kidney function, diabetes, obesity, respiratory disease, previous or current 
tumor and ischemic heart disease are comorbid conditions associated with heart failure 
(McMurray, et al., 2012) as well as inflammation (Al-shair, et al., 2011; Bondia-Pons, 
Ryan, & Martinez, 2012; Bower, Ganz, Aziz, & Fahey, 2002; Ormstad, Aass, Amthor, 
Lund-Sorensen, & Sandvik, 2011; Rosner, Ronco, & Okusa, 2012) and therefore 
possible causes of sickness behaviour. Inflammation seems to speed the progression of 
impaired cardiac function as well as to be associated with a poorer prognosis (Anand, et al., 
2005; Maeda, et al., 2000; Tsutamoto, et al., 1998). 
To our knowledge no prior studies exploring the association between inflammation and the 
sickness behavior symptom cluster have been conducted in adults with heart failure. In 
patients with chronic heart failure, fatigue, anhedonia/depression and sleepiness are common 
(Brostrom & Johansson, 2005; Johansson, Dahlstrom, & Alehagen, 2007). Some studies have 
found that depressive symptoms are associated with inflammation (Johansson, et al., 2011; 
Wirtz, et al., 2008). But none of these prior studies analyzed the cluster of sickness behaviors 
as acontributor to the inflammatory response. Such a symptom cluster may stem from an 
inflammatory response initiated by impaired cardiac function and therefore may be evidence 
of sickness behavior in heart failure patients. On the other hand, sickness behavior could also 
be due to additive effects of age related changes, such as sleepiness, anhedonia and fatigue 
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(Hunt, et al., 2010a, 2010b). We therefore sought to investigate if inflammation mediates the 
relationship between impaired cardiac function and sickness behavior in a sample of 
community dwelling older adults. 
Methods 
Participants 
The sample was derived from the epidemiological CoroKind study and has been described 
previously (Alehagen, Goetze, & Dahlstrom, 2007; Johansson, Alehagen, Svanborg, 
Dahlstrom, & Brostrom, 2009). The initial study took place between 1998 and 2000. All 
included subjects were aged 65-82 years and lived in a rural community with 10 300 
inhabitants in the southeast of Sweden. All inhabitants in this age span were invited to clinical 
and echocardiographic examinations. Of 1130 individuals in the population, 876 agreed to 
participate (participation rate 78%). From January 2003 to June 2005 the cohort was again 
contacted and invited to repeat the clinical and echocardiographic examination. A total of 675 
subjects agreed to participate. The reasons for not participating were: death (12 %), having 
moved to nursing homes or other parts of Sweden (3 %), declined (7 %) or not showing up to 
the appointment (1 %). The study protocol was approved by Regional Ethical review board of 
Linköping, Sweden. 
 
Clinical examination 
All participants were examined by a cardiologist, who took a patient history and performed a 
clinical examination. Diabetes mellitus was defined as ongoing treatment or fasting blood 
glucose ≥ 7 mmol/L. Hypertension was defined as a previous diagnosis of high blood pressure 
or a measured blood pressure of more than 140/90 mm Hg. Ischemic heart disease (IHD) was 
defined as history of angina pectoris and/or myocardial infarction. Respiratory disease was 
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established if the participant had a diagnosis or was undergoing treatment for chronic 
pulmonary disease or asthma. Previous or current tumor was defined by history. Cardiac 
function was assessed with Doppler echocardiography (Accuson XP-128c). Systolic function 
was divided semi-quantitatively by visual estimation into three classes: normal systolic 
function corresponded to a LVEF ≥ 50%; mildly impaired systolic function, LVEF 49-40%; 
and at least moderately impaired systolic function LVEF <40%. In the present study we also 
used N-terminal fragment of proBNP (NT-proBNP) as a measure of impaired cardiac 
function. All clinical examinations were based on the European Society of Cardiology’s 
guidelines for treatment of heart failure (McMurray, et al., 2012), which specify that 
echocardiography and NT-proBNP are important objective examinations to establish 
impairment of systolic function. High sensitivity C-reactive protein (CRP) was used as a 
routine marker of inflammation. 
 
Blood sampling 
Blood samples were collected while the patients were at rest in a supine position using 
EDTA-vials. The vials were chilled on ice before centrifugation at 3000 g, 4oC and then 
frozen at -70ºC. No sample was thawed more than twice. NT-proBNP was measured using an 
electrochemililuminesence immunoassay (Elecsys 2010, Roche Diagnostics, Mannheim, 
Germany). Coefficient of variation was 4.8% at 26 pmol/L and 2.1% at 503 pmol/L (n = 70). 
CRP was analysed using latex-enhanced turbidimetric immunoassay (Roche Diagnostics 
GmbH, Vienna, Austria) with a lower detection limit of 0.03 mg/L and coefficient of variation 
of 1.7%. 
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Instruments 
For sickness behaviour a combination of three instruments were used.  
The Hospital Anxiety Depression scale (HADS) measures the anhedonic aspects of 
depression (depressed sad mood and loss of interest or pleasure) and was therefore used as a 
measure of anhedonia (Zigmond & Snaith, 1983). The HADS has been used in numerous 
different types of settings (e.g., community care, primary care and hospital wards) and patient 
groups (Bjelland, Dahl, Haug, & Neckelmann, 2002) and found to be a reliable tool. Scores 
from the seven depression items range from 0-21, with higher scores indicating anhedonia 
(Zigmond & Snaith, 1983). Reliability for the HADS has been found to be 0.82 (Bjelland, 
et al., 2002). 
Fatigue was measured using the vitality scale of the SF-36. The scores range from 0-100, 
with a higher score indicating higher levels of energy (Ware & Sherbourne, 1992). The 
vitality scale of the SF-36 has been used in studies examining the association between fatigue 
and inflammation in patients with breast cancer (Bower, et al., 2002; Collado-Hidalgo, 
Bower, Ganz, Cole, & Irwin, 2006). Reliability of the vitality (i.e. fatigue) scale of the SF-
36 has been found to exceed 0.80 (Sullivan, Karlsson, & Ware, 1995). 
Sleepiness was measured with a single item (i.e., How great are the problems do you have 
with sleepiness during the day?) from the Uppsala Sleep Inventory (USI) (Liljenberg, 
Almqvist, Hetta, Roos, & Agren, 1988). The respondents rate their problems on a 5-point 
Likert scale ranging from no problems to very great problems. The whole USI has previously 
been used in surveys of both younger and elderly people, as well as patients with heart failure 
(Brostrom, Stromberg, Dahlstrom, & Fridlund, 2004; Mallon, Broman, & Hetta, 2002; Mallon 
& Hetta, 1997). This single item measure of sleepiness has been used in previous studies 
(Johansson, et al., 2009). 
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Analytic strategy and statistical analysis 
Descriptive statistics and structural equation modelling (SEM) were used to analyse the data. 
The SEM analysis was inspired by Bowers model (Bower, 2007) which describes a potential 
association between cancer and cancer treatment, inflammation, and cancer-related fatigue. In 
that model, cancer and its treatment are assumed to activate the inflammatory network which 
in turn leads to symptoms of fatigue. In our model we included “impaired cardiac function”, 
“inflammation” and “sickness behavior”. According to the inflammation hypothesis of heart 
failure, the direction of the path in the SEM was drawn from impaired cardiac function 
towards inflammation (Pasic, et al., 2003). Paths were also drawn from “inflammation” to 
“sickness behavior”, as well as between “impaired cardiac function” and “sickness behavior”. 
The latent variable “impaired cardiac function” included three classes of LVEF, and the 
cardiac biomarker NT-proBNP. Cardiovascular medications used for patients with heart 
failure, namely ACE-I, ARB, beta-blockers, and diuretics were also included since they 
can improve LVEF and decrease oedema and may thereby decrease inflammation. The 
latent factor ”inflammation” included plasma values of CRP. As sickness behavior can be 
seen as a symptom cluster (Myers, 2008), the variables anhedonia, fatigue and sleepiness 
were amalgamated to one latent factor labeled “sickness behavior”. To explore a possible 
influence of age and important comorbidities on the relationship between impaired cardiac 
function, inflammation and sickness behavior, the impact of creatinine (i.e. marker of 
impaired kidney function), blood glucose (i.e. a marker of diabetes), obesity (i.e. body mass 
index) respiratory disease, previous or current tumor and ischemic heart disease (IHD) (all 
yes/no) were examined in the basic SEM model. These illnesses were chosen because of their 
known association to impairment of cardiac function and/or inflammation and/or sickness 
behavior. 
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Categorical variables were tested with Chi-2 tests while continuous variables were analysed 
with Student’s t-test or Mann-Whitney U-test, depending on distribution of normality. SEM 
was used to explore the relationships between impaired systolic function, inflammation and 
sickness behavior. In the SEM analysis, by the means of PRELIS analysis, polychoric 
correlations were used to derive estimates of covariance. Polychoric correlations estimate the 
correlations between latent estimates of the measured variables and assume a normal 
distribution of bivariate variables. To obtain a normal distribution CRP, plasma-creatinine 
and NT-proBNP were logarithmically transformed. 
Associations in the SEM were derived using maximum likelihood methods and are described 
with their standardized coefficients. To assess Goodness of Fit the chi-square value, the Root 
Mean Square Error of Approximation (RMSEA) and Comparative Fit Index (CFI) were 
used to indicate how well the model fit in the population of community dwelling elderly. For 
the chi-square test, a high value and a significant test indicate a poor fit, but these parameters 
are influenced by sample size. An overall RMSEA below 0.06 and a CFI > 0.95 indicates a 
good fit (Schreiber, 2008). Descriptive statistical analyses were performed with SPSS 18.0 
(IBM, SPSS, Chicago, IL) and SEM analyses were performed with LISREL (Scientific 
Software International, Lincolnwood, IL). A p<0.05 in the SPSS analyses and a T-value of ≥ 
1.96 in the LISREL analyses were considered significant. 
 
Results 
Out of the 675 participants investigated, 627 (93%) had follow-up data on cardiac function, 
inflammation, anhedonia, fatigue and sleepiness (i.e. sickness behaviour). Table 1 describe 
the characteristics of the studied sample. The mean age of the sample was 78 years and 47% 
were men. The vast majority had hypertension (78%) whereas 27%, 16%, 16% and 15% had a 
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history of ischemic heart disease, diabetes, tumour or respiratory disease. Approximately one 
third of the population was on ACE-I/ARB, β-blockers and/or diuretics. About one fifth 
(21%) of the population had at least mildly impaired LVEF. Median NT-proBNP was 258 
ng/L and 25% had a plasma value >555 ng/L. Median CRP was 2.4 mg/ml with an upper 
quartile of 4.7. 
Impaired cardiac function, inflammation and sickness behaviour 
The covariance matrix used in the SEM analyses can be seen in Table 2. Figure 1 
describes the basic SEM model of the association between impaired cardiac function, 
inflammation and sickness behaviour. The fit of the model was good (Chi Square=30.5, 
p=0.10: RMSEA=0.025, CFI=0.99), demonstrating that impaired cardiac function had 
significant direct associations with inflammation (β=.26) and sickness behavior (β=.31). 
Inflammation also had a significant direct, but compared to impaired cardiac function, smaller 
association with sickness behavior (β=.21). A partial mediation was found between 
impaired cardiac function and sickness behavior mediated by inflammation (β=.05). The 
total effect of impaired cardiac function on sickness behavior was β=.36. 
To examine the influence of age, body mass index, plasma-creatinine, blood-glucose, 
respiratory disease, previous or current tumor and IHD on the associations between impaired 
cardiac function, inflammation and sickness behaviour, new SEM models were tested for each 
variable. Age (β=.39), blood glucose (β=.32), respiratory disease (β=.17), plasma-creatinine 
(β=.58) and IHD (β=.80) were all significantly associated with impaired cardiac function, 
whereas, body mass index and previous or current tumor were significantly associated with 
inflammation (β=.28 and β=.22). However, none of these new models revealed any major 
impact on the association between impaired cardiac function, inflammation and sickness 
behaviour. Both plasma-creatinine and IHD had strong associations with impaired cardiac 
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function. This is a logical finding since these can be seen as an aspect of the pathophysiology 
of heart failure. In a subsequent analysis we therefore added IHD and plasma-creatinine into 
the latent variable impaired cardiac function and explored if either variable had any impact on 
the associations between impaired cardiac function, inflammation and sickness behaviour. 
The fit of this model was also good (Chi Square=43.9, p=0.12: RMSEA=0.022, CFI=0.99). 
However, this model did not add any new information because all associations (β) were of the 
same magnitude as those found in the initial model (Figure 1). In this new model, the indirect 
effect between impaired cardiac function and sickness behavior (β=.05) mediated by 
inflammation also remained unchanged. 
 
Discussion 
In community dwelling older adults we found that inflammation was associated with a 
symptom cluster consisting of anhedonia, fatigue and sleepiness in those individuals with 
impaired cardiac function. This suggests that some of the symptoms experienced by elders 
with impaired cardiac function or heart failure represent sickness behaviour.  
In the present study sickness behaviour was defined as including anhedonia, sleepiness and 
fatigue. These symptoms may be evidence of an inflammatory component representing 
sickness behaviour, although this symptom cluster has not been investigated in such a fashion. 
In patients with cancer, investigators have found inflammation to be associated with 
depression or fatigue (Bower, et al., 2002; Bower, et al., 2011; Orre, et al., 2009). Heart 
failure is another condition which has been found to be associated to an activated 
inflammatory network (Torre-Amione, et al., 1996), with depression (Lesman-Leegte, 
Jaarsma, Sanderman, Linssen, & van Veldhuisen, 2006), sleepiness (Brostrom, et al., 2004) 
and fatigue (Falk, Patel, Swedberg, & Ekman, 2009) commonly reported. Recent studies have 
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found inflammation to be associated with depression in patients with heart failure (Johansson, 
et al., 2011; Wirtz, et al., 2009). However, these studies have only evaluated depression or 
fatigue separately and not as a symptom cluster.  
For nurses, knowledge about the underlying mechanisms of heart failure symptoms may be 
important for the development of treatment strategies. Our SEM models illustrate that 
impaired cardiac function had a direct association to sickness behaviour and inflammation. 
However, we also found inflammation to be directly associated with sickness behaviour, and 
importantly, inflammation mediated a partial indirect association between impaired cardiac 
function and sickness behaviour. Aging and comorbidity can increase inflammation and hence 
trigger sickness behaviour (Hunt, et al., 2010a). In our analysis, based on individuals mean 
aged 78 years, age and comorbid conditions were associated with impaired cardiac function 
and inflammation, but the presence of these variables did not change the associations found in 
the principal SEM model. These findings suggest that inflammation mediates the symptom 
response in elders with impaired cardiac function. From a clinical perspective, suffering from 
sickness behaviour may lead to less capability to perform daily activities. Patients may use 
this as a negative description of their self-image with wordings such as tiredness, loss of 
interest and laziness. To reduce this psychological burden, nurses can base their information 
on an explanation that this perception can originate from biological changes due to an 
impaired cardiac function. 
From a biophysical perspective, several mechanisms due to impairment of cardiac function 
can lead to inflammation and thereby to sickness behaviour. Under-perfusion of systemic 
tissue, as well as changes in the cardiac endocrine function such as increased secretion of 
brain natriuretic peptides are some mechanisms (Clerico, Giannoni, Vittorini, & Passino, 
2011; Pasic, et al., 2003). Another potential mechanism is increased permeability of the gut-
wall due to oedema. This can induce translocation of gram-negative enterobacteria and 
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secretion of endotoxin (i.e. lipopolysacharide, LPS), which is a potent stimulus of immune 
activation (Maes, Mihaylova, & Leunis, 2007). Oedematous patients with severe heart failure 
have been shown to have decreased intestinal absorption and higher plasma concentrations of 
LPS, TNF-a and TNF-receptors 1 and 2 compared non-oedematous heart failure patients and 
healthy controls (Sandek, et al., 2010). Gut-wall oedema can delay the absorption of 
medications and could hypothetically therefore be a sign of a more treatment resistant patient 
or just a patient with more severe heart failure and a worse prognosis. The impact of sickness 
behaviour has not been investigated in patients with heart failure. However, fatigue has been 
found to predict worsening heart failure (Ekman, et al., 2005). Depression (Johansson, et al., 
2007; Lesman-Leegte, et al., 2009; Sherwood, et al., 2007) and fatigue (Smith, Kupper, de 
Jonge, & Denollet, 2010) have both been found to be associated with mortality. Nurses should 
be aware of these critical pathophysiological signs of sickness behaviour, and therefore 
observant of the above mentioned symptoms/conditions among elderly patients with heart 
failure.  
Pharmacological treatment for heart failure, i.e. ACE-I/ARB, beta-blockers and diuretics, was 
in our model a part of the factor designated as impaired cardiac function. Despite the 
potential anti-inflammatory secondary effects of these cardiovascular medications (i.e., 
improved LVEF and cardiac output, decreased oedema, and decreased immune 
activation), inflammation mediated some of the association between impaired cardiac 
function and sickness behaviour. This suggests that other medications or non-pharmacological 
interventions with anti-inflammatory properties are needed to treat sickness behaviour. 
Clinical trials investigating treatment approaches of sickness behaviour are lacking. In the 
SADHART-CHF trial selective serotonin reuptake inhibitors (SSRI) was not superior to 
placebo to decrease depression in heart failure patients (O'Connor, et al., 2010). In a substudy 
of the same trial it was shown that those patients whose depression did not improve from 
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baseline levels, irrespective of SSRI or placebo, had more somatic/affective symptoms at 
baseline (Jiang, et al., 2011). Continuing depression suggests a symptom profile which could 
correspond with sickness behaviour. It is therefore possible that such aspects of sickness 
behaviour in heart failure may be less responsive to anti-depressant therapy. Statins have been 
shown to have anti-inflammatory effect in patients with coronary heart disease. Interestingly, 
in a retrospective analysis of the CORONA study, statins had favourable effects on 
cardiovascular deaths, all-cause mortality, and hospitalisations in a sub-group of patients with 
evidence of increased inflammatory activity (plasma value of CRP ≥ 2.0 mg/L) at baseline 
(McMurray, et al., 2009). Sickness behaviour was not included as an outcome in the 
CORONA trial, but these results imply that statins could be useful in heart failure patients 
with sickness behaviour.  
Other approaches to decreasing inflammation include lifestyle changes focusing on 
anhedonia, fatigue and sleepiness. Studies suggest that exercise programs can decrease 
inflammation in non-heart failure populations (Pinto, et al., 2012) as well as in heart failure 
patients (Adamopoulos, et al., 2001). There is also evidence supporting the use of exercise 
programs for depressive disorders in patients without heart failure (Dirmaier, et al., 2012). 
Limited evidence also suggests that exercise programs can improve depressive symptoms in 
heart failure patients (Koukouvou, et al., 2004; Milani, Lavie, Mehra, & Ventura, 2011). 
Whether or not exercise can improve symptoms of sickness behaviour remains to be 
elucidated.  
A limitation with the present study is that it was not specifically designed to examine an 
association between inflammation and sickness behaviour. We only had one marker of 
inflammation in our analysis. We also had a limited number of variables that could be used as 
indicators of sickness behaviour. Specifically, CRP was the only indicator of inflammation 
used. Although CRP is commonly used as a routine marker of inflammation, the 
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association between inflammation and sickness behaviour was small (β=.21) and may be 
underestimated because we did not use more direct markers of chronic inflammation 
such as interleukin-1, interleukin-6 or tumour necrosis alpha (TNF-a), the key cytokines 
triggering sickness behaviour (Dantzer, 2006). Another methodological reason for the low 
correlations found could be that data in this study were collected from community-dwelling 
older adults who may not have been sufficiently ill to demonstrate more robust associations. 
However, the association between different inflammatory markers and fatigue in cancer 
patients rarely exceeded r=.20; the highest correlation was r=.29 (Schubert, Hong, Natarajan, 
Mills, & Dimsdale, 2007). A clinical reason for these low correlations could be that the 
symptoms included in the  sickness behaviour cluster (anhedonia, fatigue, sleepiness) are not 
only caused by inflammation but may also occur as a response to other stressors such as low 
socio-economic status or bereavement (Cole & Dendukuri, 2003; Skobel, et al., 2005). 
Unfortunately, data on obstructive sleep apnea, cognitive impairment, lethargy, loss of 
appetite, hyperalgesia and physical capacity, also known to trigger inflammation, were not 
available for inclusion in the model. This may have underestimated the associations found 
between inflammation and sickness behaviour in the present study. Moreover, because of the 
cross-sectional study design the associations presented in the SEM models cannot be 
interpreted as strict causal relationships.  
In summary, we have shown that inflammation and impaired systolic function both were 
associated with a symptom cluster of anhedonia, fatigue and sleepiness in community 
dwelling older adults. Our results imply that this symptom cluster could represent sickness 
behaviour in patients with heart failure. If these associations are supported in future research, 
innovative intervention approaches are needed for patients with heart failure and sickness 
behaviour. 
 16 
 
Figure 
Figure 1. Structural equation model of the associations (Beta weights) between impaired systolic function, inflammation and sickness behavior. 
The factor loadings are in italics. All effects and loadings shown are significant (t<1.96). Impaired cardiac function had a significant direct but 
also a significant indirect effect (.05) on sickness behavior mediated by inflammation. 
 
 17 
 
Impaired 
cardiac 
function 
ACE/ARB 
β-blockers 
 
Diuretics 
 LVEF  
Sleepiness 
 
Anhedonia 
 
Fatigue 
 
CRP 
 
.31 
.26 .21 
Goodness of fit statistics 
Chi square = 30.5 p = 0.10 
RMSEA = 0.025: CFI = 0.99 
Sickness 
behavior 
Inflammation 
.57 
.59 
.87 
.59 
.32 .51 
.37 
.62 
NT-proBNP .58 
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 Table 1. Demographic and medical characteristics of the study sample (N = 627). 
Characteristic Value 
Age, mean (SD) 78 (4) 
Sex, male % (n) 47 (296) 
Body mass index, mean (SD) 27.1 (4.2) 
Systolic blood pressure, mean (SD) 149 (23) 
Diastolic blood pressure, mean (SD) 75 (11) 
Diabetes, % (n) 16 (102) 
Hypertension, % (n) 78 (486) 
Ischemic heart disease, % (n) 27 (170) 
Previous or present tumor, % (n) 16 (103) 
Respiratory disease, % (n) 15 (96) 
Left ventricular ejection fraction, % (n)  
≥ 50% 79 (495) 
49–40% 13 (81) 
< 40% 8 (51) 
NT-proBNP ng/L, median (25th–75th quart) 258 (140–555) 
CRP mg/L, median (25th–75th quart) 2.4 (1.1–4.7) 
Creatinine µmol/L , median (25th–75th quart) 74 (63–90) 
Blood glucose mmol/L, mean (SD) 5.8 (2.2) 
ACE/ARB, % (n) 26 (162) 
β-blockers, % (n) 36 (230) 
Diuretics, % (n) 35 (221) 
Anhedonia (HADS), mean (SD) 3.8 (2.6) 
Fatigue (vitality scale SF-36), mean (SD) 61.5 (22) 
Sleepiness, mean (SD) 2.2 (0.9) 
Note. ACE/ARB = Angiotensin converting enzyme inhibitor/angiotensin receptor blockade; 
CRP = C-reactive protein; HADS = Hospital Anxiety Depression Scale; NT-proBNP = N-
terminal of probrain natriuretic peptide. 
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Table 2. Estimates of covariance of the variables used in the semi-structural equation analyses. The correlations were derived by means of 
PRELIS analysis.  
 
NT-
proBNP CRP 
Anhedo
-nia Sleepiness Fatigue BMI Creatinine 
B-
glucose 
Resp 
Dis. Tumour 
ACE/
ARB 
B-
blocker Diuretics Age IHD LVEF 
NT-
proBNP 1.0                
CRP 0.140 1.0               
Anhedonia 0.082 0.088 1.0              
Sleepiness 0.116 0.116 0.355 1.0             
Fatigue 0.220 0.153 0.515 0.489 1.0            
BMI -0.06 0.182 -0.025 0.027 0.038 1.0           
Creatinine 0.209 0.158 0.069 0.104 0.116 0.064 1.0          
B-glucose 0.032 0.099 -0.016 0.034 0.105 0.172 0.114 1.0         
Resp-Dis. 0.088 0.127 0.026 0.103 0.141 0.070 0.042 0.020 1.0        
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Tumour 0.045 0.137 -0.065 0.111 0.068 0.133 0.018 -0.017 0.026 1.0       
ACE/ARB 0.154 0.048 0.101 0.149 0.186 0.200 0.185 0.258 0.157 0.071 1.0      
B-blocker 0.299 0.049 0.034 0.100 0.127 0.122 0.053 0.074 0.020 0.126 0.219 1.0     
Diuretics 0.202 0.157 0.042 0.101 0.163 0.235 0.131 0.101 0.199 0.242 0.458 0.332 1.0    
Age 0.364 0.049 -0.010 0.099 0.196 -0.092 0.137 0.082 0.028 0.083 0.032 0.029 0.041 1.0   
IHD 0.246 0.052 0.054 0.159 0.160 0.027 0.160 0.128 0.100 0.054 0.223 0.516 0.123 0.257 1.0  
LVEF 0.369 0.074 0.109 0.091 0.181 -0.007 0.251 0.107 0.003 0.012 0.236 0.319 0.163 0.284 0.475 1.0 
Note: ACE/ARB = angiotensin converting enzyme inhibitor/angiotensin receptor blockade; B-glucose = beta glucose; BMI = body mass index; 
CRP = C-reactive protein; IHD = ischemic heart disease; LVEF = left ventricular ejection fraction; NT-proBNP = N-terminal of probrain 
natriuretic peptide; Tumor = previous or present tumor; Resp Dis = respiratory disease. 
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